Kidney cancer research includes IO/targeted combinations, adjuvant strategies, and risk-adapted approaches in clear-cell and non-clear-cell RCC.
In a correlative biomarker analysis of the HCRN GU16-260 trial, non-exhausted CD8+ T cells were linked to higher response rates and longer progression-free survival in treatment-naive metastatic clear-cell RCC treated with first-line nivolumab.
Related topics: Immunotherapy Response Biomarkers
Please enable JavaScript to access the latest cancer research articles and studies.